| Ibrutinib in previously treated Waldenström’s macroglobulinemia SP Treon, CK Tripsas, K Meid, D Warren, G Varma, R Green, ... New England Journal of Medicine 372 (15), 1430-1440, 2015 | 984 | 2015 |
| Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis AM Petrich, M Gandhi, B Jovanovic, JJ Castillo, S Rajguru, DT Yang, ... Blood, The Journal of the American Society of Hematology 124 (15), 2354-2361, 2014 | 518 | 2014 |
| Breast implant–associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients RN Miranda, TN Aladily, HM Prince, R Kanagal-Shamanna, D De Jong, ... Journal of clinical oncology 32 (2), 114, 2014 | 447 | 2014 |
| The biology and treatment of plasmablastic lymphoma JJ Castillo, M Bibas, RN Miranda Blood, The Journal of the American Society of Hematology 125 (15), 2323-2330, 2015 | 445 | 2015 |
| A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study CS Tam, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, ... Blood, The Journal of the American Society of Hematology 136 (18), 2038-2050, 2020 | 365 | 2020 |
| HIV‐associated plasmablastic lymphoma: lessons learned from 112 published cases J Castillo, L Pantanowitz, BJ Dezube American journal of hematology 83 (10), 804-809, 2008 | 351 | 2008 |
| The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19–infected patients SP Treon, JJ Castillo, AP Skarbnik, JD Soumerai, IM Ghobrial, ... Blood, The Journal of the American Society of Hematology 135 (21), 1912-1915, 2020 | 308 | 2020 |
| Diagnosis and management of hyponatremia in cancer patients JJ Castillo, M Vincent, E Justice The oncologist 17 (6), 756-765, 2012 | 275 | 2012 |
| Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma JJ Castillo, ES Winer, D Stachurski, K Perez, M Jabbour, C Milani, ... Leukemia & lymphoma 51 (11), 2047-2053, 2010 | 235 | 2010 |
| Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial MA Dimopoulos, J Trotman, A Tedeschi, JV Matous, D Macdonald, C Tam, ... The Lancet Oncology 18 (2), 241-250, 2017 | 234 | 2017 |
| The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia Y Cao, ZR Hunter, X Liu, L Xu, G Yang, J Chen, CJ Patterson, ... Leukemia 29 (1), 169-176, 2015 | 233 | 2015 |
| Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies JJ Castillo, N Mull, JL Reagan, S Nemr, J Mitri Blood, The Journal of the American Society of Hematology 119 (21), 4845-4850, 2012 | 229 | 2012 |
| Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database AJ Olszewski, JJ Castillo Cancer 119 (3), 629-638, 2013 | 227 | 2013 |
| Treatment recommendations from the Eighth International Workshop on Waldenström’s macroglobulinemia V Leblond, E Kastritis, R Advani, SM Ansell, C Buske, JJ Castillo, ... Blood, the Journal of the American Society of Hematology 128 (10), 1321-1328, 2016 | 199 | 2016 |
| Diabetes and risk of Non-Hodgkin's lymphoma: a meta-analysis of observational studies J Mitri, J Castillo, AG Pittas Diabetes care 31 (12), 2391-2397, 2008 | 187 | 2008 |
| Human immunodeficiency virus‐associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy JJ Castillo, M Furman, BE Beltrán, M Bibas, M Bower, W Chen, ... Cancer 118 (21), 5270-5277, 2012 | 186 | 2012 |
| Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology SK Kumar, NS Callander, K Adekola, L Anderson, M Baljevic, ... Journal of the National Comprehensive Cancer Network 18 (12), 1685-1717, 2020 | 185 | 2020 |
| Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia SP Treon, J Gustine, K Meid, G Yang, L Xu, X Liu, M Demos, A Kofides, ... Journal of Clinical Oncology 36 (27), 2755-2761, 2018 | 182 | 2018 |
| Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia SP Treon, CK Tripsas, K Meid, S Kanan, P Sheehy, S Chuma, L Xu, ... Blood, The Journal of the American Society of Hematology 124 (4), 503-510, 2014 | 177 | 2014 |
| Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma JJ Castillo, ES Winer, D Stachurski, K Perez, M Jabbour, C Milani, ... The oncologist 15 (3), 293-299, 2010 | 172 | 2010 |
Zachary Hunter, PhDDana-Farber Cancer Institute - Bing Center for WMVerified email at dfci.harvard.edu
